Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation

This study has been completed.
Information provided by:
Novo Nordisk A/S Identifier:
First received: March 22, 2012
Last updated: December 10, 2012
Last verified: December 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2003
  Primary Completion Date: October 2003 (Final data collection date for primary outcome measure)